BL 1021

Drug Profile

BL 1021

Alternative Names: BL-1021

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bar-Ilan-Research-&-Development-Company; Ramot at Tel Aviv University
  • Developer BioLineRx
  • Class Analgesics; Anti-inflammatories; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Neuropathic pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Israel (PO)
  • 07 May 2012 BL 1021 is available for licensing as of 22 Mar 2012. http://www.biolinerx.com
  • 06 Dec 2011 Final adverse events & pharmacokinetics data from a phase I trial in Healthy volunteers released by BioLineRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top